SHAREHOLDER ALERT:  Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI


BALA CYNWYD, June 6, 2017 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Albany Molecular Research, Inc. (“Albany Molecular” or “the Company”) (Nasdaq- AMRI-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to The Carlyle Group and GTCR (“The Carlyle Group”).

Under the terms of the transaction, Albany Molecular shareholders will receive only $21.75 in cash for each share of Albany Molecular stock they own. The investigation concerns whether the Board of  Albany Molecular breached their fiduciary duties to shareholders and whether The Carlyle Group is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many long term holders of Albany Molecular stock. For example, shares of Albany Molecular stock have traded as high as $61.63 per share.

If you own shares of Albany Molecular stock and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004 or calling toll  free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.